Paper Details

  1. Home
  2. Paper Details

Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.

Author: , AlejosBelén, BernalEnrique, García YuberoCristina, JarrínInma, MorenoCristina, Pérez-IsLaura, Ruiz-AlgueróMarta, Samperiz AbadGloria, Suárez-GarcíaInés, ZuberoZuriñe, de Zárraga FernándezMiguel Alberto

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dolutegravir (DTG) plus abacavir (ABC)/lamivudine (3TC) administered as two separate pills, either branded or generic ABC/3TC, was as effective and tolerable as the single tablet regimen (STR) DTG/ABC/3TC in 829 treatment-naïve individuals. Switching from STR to DTG+(ABC/3TC)g did not impair effectiveness in 177 virologically suppressed individuals.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: We aimed to assess the effectiveness and tolerability of dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) administered as branded STR (DTG/ABC/3TC) or as two separate pills (DTG and either branded ABC/3TC [DTG+(ABC/3TC)b] or generic ABC/3TC [DTG+(ABC/3TC)g]). METHODS: We includ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295592/

データ提供：米国国立医学図書館（NLM）

Dolutegravir and Abacavir/Lamivudine: A Comparison of Single-Tablet Regimen and Separate Pills

In the vast desert of HIV/AIDS treatment, researchers are constantly searching for optimal regimens to suppress the virus and improve patient outcomes. This research explored the effectiveness and tolerability of a common HIV treatment regimen, dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC), comparing the single-tablet regimen (STR) to administering the medications as separate pills.

Single-Tablet Regimen vs. Separate Pills: A Tale of Two Approaches

The study, a multicenter cohort in Spain, found no significant differences in viral suppression rates at 24 weeks between individuals starting with DTG/ABC/3TC (STR) and those receiving DTG and either branded or generic ABC/3TC as separate pills. The study also found that switching from STR to separate pills did not significantly impact viral suppression in those already virally suppressed.

Navigating the Treatment Landscape: Flexibility and Choice for Patients

This research highlights the importance of offering patients flexible treatment options, allowing them to choose the approach that best suits their individual needs and preferences. It also emphasizes the value of generic medications, demonstrating that they can be equally effective and well-tolerated as their branded counterparts. It's like a desert traveler who can choose different routes to reach their destination, each with its own unique challenges and benefits.

Dr.Camel's Conclusion

This study provides valuable insight into the evolving landscape of HIV/AIDS treatment, demonstrating that flexibility and patient choice are essential elements of effective care. It's a reminder that the journey of HIV treatment is a collaborative one, with healthcare providers and patients working together to navigate the complexities of the disease and find the best possible approach for each individual.

Date :
  1. Date Completed 2021-10-25
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34291580

DOI: Digital Object Identifier

PMC8295592

Related Literature

Article Analysis
・Side Effects of 3tc・Side Effects of abacavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.